Coaprovel 300 mg/25 mg film-coated tablets

Spain
Brand name Coaprovel 300 mg/25 mg film-coated tablets
Form tablets, film-coated
Active substance / Dosage
Prescription type Prescription Only Medicine
Registration number 98086024
Coaprovel 300 mg/25 mg film-coated tablets tablets, film-coated

Package leaflet: Information for the patient

Introduction

Package leaflet: information for the patient CoAprovel 300 mg/25 mg film-coated tablets

Irbesartan/hydrochlorothiazide

Read the entire leaflet carefully before you start taking this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only and must not be given to other people, even if they have the same symptoms as you, because it could harm them.
  • If you experience any side effects, talk to your doctor or pharmacist, even if they are side effects not listed in this leaflet. See section 4.

Contents of the leaflet

  1. What CoAprovel is and what it is used for
  2. What you need to know before taking CoAprovel
  3. How to take CoAprovel
  4. Possible side effects
  5. How to store CoAprovel
  6. Contents of the pack and other information

1. What CoAprovel is and what it is used for

CoAprovel is a combination of two active substances, irbesartan and hydrochlorothiazide.

Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists.

Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels, causing them to constrict. This leads to an increase in blood pressure. Irbesartan prevents angiotensin-II from binding to these receptors, relaxing the blood vessels and thereby reducing blood pressure.

Hydrochlorothiazide belongs to a group of medicines (called thiazide diuretics) that lower blood pressure by increasing the amount of urine produced.

The two active substances in CoAprovel work together to achieve a greater reduction in blood pressure than either of them alone.

CoAprovel is used to treat high blood pressure when treatment with either irbesartan or hydrochlorothiazide alone does not provide adequate control of blood pressure.

2. What you need to know before taking CoAprovel

Do not take CoAprovel

  • if you are allergic to irbesartan or to any of the other ingredients of this medicine (listed in section 6)
  • if you are allergic to hydrochlorothiazide or any other sulfonamide-derived medicine
  • if you are more than 3 months pregnant. (In any case, it is better to avoid taking this medicine also during early pregnancy – see section “Pregnancy”)
  • if you have severe liver or kidney problems
  • if you have difficulty passing urine
  • if your doctor finds that you have persistently high levels of calcium or low levels of potassium in your blood
  • if you have diabetes or kidney failure and are being treated with a blood pressure-lowering medicine containing aliskiren.

Warnings and precautions

Talk to your doctor before starting to take CoAprovel and in any of the following cases:

  • if you have excessive vomiting or diarrhoea

  • if you have kidney problems or have had a kidney transplant

  • if you have heart problems

  • if you have liver problems

  • if you have diabetes

  • if you have low blood sugar levels (symptoms may include sweating, weakness, hunger, dizziness, trembling, headache, flushing or paleness, numbness, rapid and strong heartbeat), especially if you are being treated for diabetes

  • if you have lupus erythematosus (also known as lupus or SLE)

  • if you have primary hyperaldosteronism (a condition related to excessive production of the hormone aldosterone, leading to sodium retention and, in turn, increased blood pressure)

  • if you are taking any of the following medicines used to treat high blood pressure (hypertension):

  • an angiotensin-converting enzyme inhibitor (ACE inhibitor) (e.g. enalapril, lisinopril, ramipril), particularly if you have kidney problems related to diabetes.

  • aliskiren.

    • if you have had skin cancer or develop an unexpected skin lesion during treatment. Treatment with hydrochlorothiazide, particularly long-term use at high doses, may increase the risk of certain types of non-melanoma skin cancer and lip cancer. Protect your skin from exposure to sunlight and UV rays while taking CoAprovel.
    • if you have previously experienced respiratory or lung problems (such as inflammation or fluid in the lungs) after taking hydrochlorothiazide. If you develop shortness of breath or severe difficulty breathing after taking CoAprovel, seek medical attention immediately.

Your doctor may monitor your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.

Talk to your doctor if you experience abdominal pain, nausea, vomiting, or diarrhoea after taking CoAprovel. Your doctor will decide whether to continue treatment. Do not stop taking CoAprovel monotherapy without medical advice.

See also the information under the heading “Do not take CoAprovel”.

If you are pregnant, think you may be pregnant, or plan to become pregnant, you must inform your doctor. Use of CoAprovel is not recommended during the first trimester of pregnancy (first 3 months), and it must not be used from the third month of pregnancy onwards, as it may cause serious harm to your baby (see section “Pregnancy”).

You should also inform your doctor if:

  • you are on a low-salt diet
  • you experience any of the following signs: feeling thirsty, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or rapid heartbeat, as these may indicate an excessive effect of hydrochlorothiazide (contained in CoAprovel)
  • you experience increased skin sensitivity to sunlight, with symptoms of sunburn (such as redness, itching, swelling, blisters) occurring more quickly than usual
  • you are going to have surgery (a surgical procedure) or will be given anaesthetics
  • you experience decreased vision or eye pain in one or both eyes while taking CoAprovel. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or increased eye pressure (glaucoma), which may occur within hours to a week after taking CoAprovel. This may lead to permanent vision loss if not treated. If you previously had an allergy to penicillin or sulfonamides, you may have a higher risk of developing this. You must stop treatment with CoAprovel and seek immediate medical attention.

The hydrochlorothiazide contained in this medicine may cause positive results in doping controls.

Children and adolescents

CoAprovel must not be given to children and adolescents (under 18 years of age).

Taking CoAprovel with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might need to use any other medicines.

Diuretics such as hydrochlorothiazide contained in CoAprovel may interact with other medicines. You must not take preparations containing lithium together with CoAprovel without medical supervision.

Your doctor may need to adjust your dose and/or take other precautions if you are taking:

  • an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also information under the headings “Do not take CoAprovel” and “Warnings and precautions”).

You may need blood tests if you are taking:

  • potassium supplements
  • salt substitutes containing potassium
  • potassium-sparing medicines or other diuretics (tablets that increase urine production)
  • certain laxatives
  • medicines used to treat gout
  • vitamin D supplements
  • medicines to control heart rhythm
  • medicines for diabetes (oral agents such as repaglinide or insulin)
  • carbamazepine (a medicine used to treat epilepsy)

It is also important to inform your doctor if you are taking other blood pressure-lowering medicines, steroids, cancer treatments, painkillers, arthritis medicines, or cholestyramine or colestipol resins to reduce blood cholesterol.

Taking CoAprovel with food, drink, and alcohol

CoAprovel can be taken with or without food.

Due to the hydrochlorothiazide contained in CoAprovel, if you drink alcohol while taking this medicine, you may feel more dizzy when standing up, especially when rising from a sitting position.

Pregnancy, breastfeeding, and fertility

Pregnancy

Inform your doctor if you are pregnant, think you may be pregnant, or plan to become pregnant. Your doctor will usually advise you to stop taking CoAprovel before becoming pregnant or as soon as pregnancy is confirmed, and will recommend an alternative antihypertensive medicine. CoAprovel is not recommended during early pregnancy and must not be used from the third month of pregnancy onwards, as it may cause serious harm to your baby when used from that time.

Breastfeeding

Inform your doctor if you are breastfeeding or plan to breastfeed, as CoAprovel is not recommended for women during this period. Your doctor may choose a different treatment that is more suitable, especially if you are breastfeeding a newborn or premature infant.

Driving and using machines

CoAprovel is unlikely to affect your ability to drive or use machines. However, during treatment for hypertension, dizziness or fatigue may occasionally occur. If you experience these symptoms, talk to your doctor before driving or operating machinery.

CoAprovel contains lactose. If your doctor has told you that you have an intolerance to certain sugars (e.g. lactose), consult with him before taking this medicine.

CoAprovel contains sodium. This medicine contains less than 1 mmol of sodium (23 mg) per tablet, i.e., essentially "sodium-free".

3. How to take CoAprovel

Follow exactly the instructions for using this medicine as given by your doctor. If in doubt, consult your doctor or pharmacist again.

Dosage

The recommended dose of CoAprovel is one tablet daily. In general, your doctor will prescribe CoAprovel when previous treatments you have received have not sufficiently reduced your blood pressure. Your doctor will advise you on how to switch from previous treatments to CoAprovel.

Method of administration

CoAprovel is administered orally. The tablets should be swallowed with a sufficient amount of liquid (e.g. a glass of water). You may take CoAprovel with or without food. You should try to take your daily dose at the same time each day. It is important that you continue taking CoAprovel until your doctor advises you otherwise.

Maximum blood pressure-lowering effect should be reached within 6–8 weeks after starting treatment.

If you take more CoAprovel than you should

If you accidentally take too many tablets, contact your doctor immediately.

Children must not take CoAprovel

CoAprovel must not be given to children under 18 years of age. If a child swallows any tablets, contact your doctor immediately.

If you forget to take CoAprovel

If you accidentally miss a dose, simply take your next dose at the usual time. Do not take a double dose to make up for missed doses.

If you have any further questions about the use of this medicine, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, CoAprovel can cause adverse effects, although not everyone experiences them.

Some of these effects may be serious and may require immediate medical attention.

Rare cases of skin allergic reactions (rash, urticaria) have been reported in patients treated with irbesartan, as well as localized swelling of the face, lips and/or tongue. If you experience any of the above symptoms or develop shortness of breath, stop taking CoAprovel and contact your doctor immediately.

The frequency of the adverse effects listed below is defined using the following convention:

Frequent: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people

Adverse effects reported in clinical studies for patients treated with CoAprovel were:

Frequent adverse effects (may affect up to 1 in 10 people):

  • nausea/vomiting
  • urinary abnormalities
  • fatigue
  • dizziness (including dizziness upon standing from a lying or sitting position)
  • blood tests may show elevated levels of an enzyme that measures muscle and heart function (creatine kinase) or elevated levels of substances that measure kidney function (blood urea nitrogen, creatinine).

If any of these adverse effects cause you problems, consult your doctor.

Uncommon adverse effects (may affect up to 1 in 100 people):

  • diarrhea
  • low blood pressure
  • fainting
  • tachycardia
  • flushing
  • swelling due to fluid retention (edema)
  • sexual dysfunction (sexual function disorders)
  • blood tests may show low levels of sodium and potassium in your blood.

If any of these adverse effects cause you problems, consult your doctor.

Adverse effects reported since CoAprovel was marketed

Since CoAprovel has been marketed, some adverse effects have been reported. Adverse effects observed with frequency not known are: headache, tinnitus (ringing in the ears), cough, altered taste, indigestion, joint and muscle pain, liver function abnormalities, kidney failure, elevated potassium levels in the blood, and allergic reactions such as rash, urticaria, and swelling of the face, lips, mouth, tongue, or throat. Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been observed.

As with all fixed combinations of two active substances, adverse effects associated with each individual component cannot be excluded.

Adverse effects associated solely with irbesartan

In addition to the adverse effects described above, chest pain, severe allergic reactions (anaphylactic shock), decreased number of red blood cells (anemia – symptoms may include tiredness, headache, shortness of breath on exertion, dizziness, and pallor), decreased platelet count (a blood cell essential for blood clotting), and low blood sugar levels have also been observed.

Rare (may affect up to 1 in 1,000 people): intestinal angioedema: swelling in the intestine presenting symptoms such as abdominal pain, nausea, vomiting, and diarrhea.

Adverse effects associated with hydrochlorothiazide in monotherapy

Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterized by severe upper abdominal pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; low white blood cell count, which may lead to frequent infections and fever; decreased platelet count (blood cells essential for blood clotting), decreased red blood cell count (anemia) characterized by fatigue, headache, shortness of breath on exertion, dizziness, and pallor; kidney disease; lung disorders including pneumonia or fluid accumulation in the lungs; increased skin sensitivity to sunlight; inflammation of blood vessels; a skin disorder characterized by peeling of the skin over the entire body; cutaneous lupus erythematosus, identified by a rash that may appear on the face, neck, and scalp; allergic reactions; muscle weakness and spasms; irregular heart rhythm; drop in blood pressure after a change in body position; swelling of the salivary glands; high blood sugar levels; sugar in the urine; increases in certain types of blood fats; high levels of uric acid in the blood, which may cause gout.

Very rare: Acute breathing difficulty (symptoms include severe shortness of breath, fever, weakness, and confusion).

Frequency not known (cannot be estimated from available data): Skin and lip cancer (non-melanoma skin cancer), reduced vision or eye pain due to elevated pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).

It is known that adverse effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.

Reporting of adverse effects

If you experience any adverse effect, talk to your doctor or pharmacist, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly through the national reporting system detailed in Appendix V. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of CoAprovel

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month indicated.

Do not store above 30 °C.

Store in the original packaging to protect from moisture.

Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines and packaging that you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of CoAprovel

  • The active substances are irbesartan and hydrochlorothiazide. Each CoAprovel 300 mg/25 mg film-coated tablet contains 300 mg of irbesartan and 25 mg of hydrochlorothiazide.
  • The other components are monohydrate lactose, microcrystalline cellulose, sodium croscarmellose, hypromellose, colloidal anhydrous silica, magnesium stearate, titanium dioxide, macrogol 3350, red, yellow and black iron oxides, pregelatinized starch, carnauba wax. See section 2 "CoAprovel contains lactose".

Nature and contents of the container

CoAprovel 300 mg/25 mg film-coated tablets are pink, biconvex, oval-shaped tablets, with a heart-shaped breakline on one side and the number 2788 engraved on the other.

CoAprovel 300 mg/25 mg film-coated tablets are available in blister packs containing 14, 28, 30, 56, 84, 90 or 98 film-coated tablets. It is also available in unit-dose blister packs of 56 x 1 film-coated tablet for hospital supply.

Only certain pack sizes may be marketed.

Marketing Authorisation Holder

Sanofi Winthrop Industrie

82 avenue Raspail

94250 Gentilly

France

Manufacturer

SANOFI WINTHROP INDUSTRIE
1, rue de la Vierge
Ambarès & Lagrave
F-33565 Carbon Blanc Cedex - France

SANOFI WINTHROP INDUSTRIE
30-36 Avenue Gustave Eiffel
37100 Tours - France

For further information regarding this medicinal product, please contact the local representative of the Marketing Authorisation Holder:

Belgium/Belgium/Belgium

Sanofi Belgium

Tel/Tel: +32 (0)2 710 54 00

Luxembourg/Luxembourg

Sanofi Belgium

Tel/Tel: +32 (0)2 710 54 00 (Belgium/Belgium)

Text in Cyrillic characters with the inscription България, the name Swixx Biopharma EOOD, and the telephone number +359 (0)2 4942 480

Hungary

sanofi-aventis zrt., Hungary

Tel.: +36 1 505 0050

Czech Republic

Sanofi, s.r.o.

Tel: +420 233 086 111

Malta

Sanofi S.r.l.

Tel: +39 02 39394275

Denmark

Sanofi A/S

Tlf: +45 45 16 70 00

Netherlands

Sanofi B.V.

Tel: +31 20 245 4000

Germany

Sanofi-Aventis Deutschland GmbH

Tel: 0800 52 52 010

Tel. from abroad: +49 69 305 21 131

Norway

sanofi-aventis Norge AS

Tlf: +47 67 10 71 00

Estonia

Swixx Biopharma OÜ

Tel: +372 640 10 30

Austria

sanofi-aventis GmbH

Tel: +43 1 80 185 – 0

Greece

Sanofi-Aventis Monoprosopi EPE

Tel: +30 210 900 16 00

Poland

Sanofi Sp. z o.o.

Tel.: +48 22 280 00 00

Spain

sanofi-aventis, S.A.

Tel: +34 93 485 94 00

Portugal

Sanofi - Produtos Farmacêuticos, Lda

Tel: +351 21 35 89 400

France

Sanofi Winthrop Industrie

Tél: 0 800 222 555

Call from abroad: +33 1 57 63 23 23

Croatia

Swixx Biopharma d.o.o.

Tel: +385 1 2078 500

Romania

Sanofi Romania SRL

Tel: +40 (0) 21 317 31 36

Ireland

sanofi-aventis Ireland Ltd.

Tel: +353 (0) 1 403 56 00

Slovenia

Swixx Biopharma d.o.o.

Tel: +386 1 235 51 00

Iceland

Vistor hf. T/A SANOFI

Sími: +354 535 7000

Slovakia

Swixx Biopharma s.r.o.

Tel: +421 2 208 33 600

Italy

Sanofi S.r.l.

Tel: 800.536389

Finland

Sanofi Oy

Puh/Tel: +358 (0) 201 200 300

Cyprus

C.A. Papaellinas Ltd.

Tel: +357 22 741741

Sweden

Sanofi AB

Tel: +46 (0)8 634 50 00

Latvia

Swixx Biopharma SIA

Tel: +371 6616 47 50

United Kingdom (Northern Ireland)

sanofi-aventis Ireland Ltd. T/A SANOFI

Tel: +44 (0) 800 035 2525

Lithuania

Swixx Biopharma UAB

Tel: +370 5 236 91 40

Date of the most recent review of this leaflet:

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.